Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 6;15:6672. doi: 10.1038/s41467-024-50908-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 6 — A Schematic representation of the experimental procedure for RNA sequencing following drug treatment. B Number of genes deregulated in VCaP cells treated with PF-9366 or AG-270, compared to VCaP control cells. C Heatmap of differentially expressed genes in VCaP cells treated with either PF-9366 or AG-270, versus control VCaP cells. D PCA plot of VCaP cells, colored according to the conditions (CTRL, PF-9366 and AG-270). E Hallmark enrichment analysis of VCaP MAT2Akd (Sh1 and Sh2), VCaP treated with either PF-9366 or AG-270 versus respective control samples. Down-regulated pathways are colored in blue, up-regulated pathways are colored in red. F Convergence between MAT2Ai and MAT2Akd deregulated targets with threshold on Log2FC ± 0.1 (up-regulated and down-regulated genes as indicated). Top, overlap with genes deregulated by PF-9366. Bottom, overlap with genes deregulated by AG-270. G Functional annotation of convergent genes deregulated by AG-270, PF-9366 and MAT2Akd. Pathways upregulated and downregulated are shown in the left and right panel, respectively. Adjusted p-value ≤ 0.01. H Cumulative gene expression level of convergent up-regulated genes (1053) by PF-9366 and AG-270 and MAT2Akd in VCaP cells, in the cohort of primary, CRPC and NEPC patients. I Cumulative gene expression level of convergent down-regulated genes (963) by PF-9366 and AG-270, and MAT2Akd in VCaP cells, in the cohort of primary, CRPC and NEPC patients. Primary, n = 714; CRPC, n = 316; NEPC, n = 19. For box-and-whisker plots in H and I, the line inside the box shows the median value. The bounds of the box represent the 25th–75th percentiles, with whiskers at minimum and maximum values. One-way-ANOVA was used to test significant differences between groups. Panel A Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.